Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07089121 · ClinicalTrials.gov registry record · Phase 1
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
A Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV), sponsored by Cartesian Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07089121 is a Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV) that is actively recruiting participants, run by Cartesian Therapeutics. The registered enrollment target is 50 participants, below the 1,885-participant average among 3 other Juvenile Dermatomyositis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07089121, a Phase 1 study of Juvenile Dermatomyositis and ANCA-Associated Vasculitis (AAV), is actively recruiting participants, sponsored by Cartesian Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
Conditions Studied
Interventions
- DRUG Descartes-08
Study Locations (1)
Missouri
- H03 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07089121
The ClinicalTrials.gov registry entry for NCT07089121 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,885-participant average among 3 other Juvenile Dermatomyositis trials with a reported enrollment target (97% lower). The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Juvenile Dermatomyositis appearing as the primary indexed condition, and to 1 intervention - of which Descartes-08 is the first listed.
NCT07089121 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07089121 about?
NCT07089121 is a clinical study titled "Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders". Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis
What is the current status of trial NCT07089121?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-01. Estimated completion is 2026-12.
What conditions does trial NCT07089121 study?
This clinical trial studies the following conditions: Juvenile Dermatomyositis, ANCA-Associated Vasculitis (AAV), Childhood-onset Systemic Lupus Erythematous, Juvenile Myasthenia Gravis.
What interventions are being tested in trial NCT07089121?
The interventions under investigation include: Descartes-08 (DRUG).
Who is sponsoring clinical trial NCT07089121?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07089121 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
RECRUITING
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Environmental Risk Factors for the Anti-synthetase Syndrome
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.